NNV024, a novel humanized anti-CD37 antibody with enhanced ADCC and prolonged plasma half-life in human FcRn transgenic mice for treatment of NHL
Roman Generalov(Nordic Nanovector (Norway)), Jostein Dahle(Oslo University Hospital), Véronique Pascal(Nordic Nanovector (Norway)), Elisa Fiorito(Oslo University Hospital), Helèn Heyerdahl(Nordic Nanovector (Norway)), Sigrid S. Skånland(Oslo University Hospital), Stian Foss(University of Oslo), Geir E. Tjønnfjord(Oslo University Hospital), Ada H. V. Repetto‐Llamazares(Nordic Nanovector (Norway)), Jan Terje Andersen(Oslo University Hospital)
Cited by 0
Related Papers
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
|Frontiers in Immunology|2015|297
Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders
|Journal of Allergy and Clinical Immunology|2016|282
DISTRIBUTION OF 5‐AMINOLEVULINIC ACID‐INDUCED PORPHYRINS IN NODULOULCERATIVE BASAL CELL CARCINOMA
|Photochemistry and Photobiology|1995|181
Cold agglutinin disease revisited: a multinational, observational study of 232 patients
|Blood|2020|167
TRIM21—From Intracellular Immunity to Therapy
|Frontiers in Immunology|2019|146